• June 24, 2022

    Outstanding First Half for Paragon and its Portfolio Companies

    Paragon and its portfolio companies continue to [...]

  • May 25, 2022

    Castle Creek Biosciences Raises $112.8 Million to Advance Novel Gene Therapies and Expand Pipeline

    – Funding expected to provide sufficient capital [...]

  • April 5, 2022

    Evozyne Announces Multi-Target Research Collaboration and License Agreement with Takeda to Develop Next-Generation Gene Therapies

    Expansion builds on initial strategic collaboration and [...]

  • March 1, 2022

    Emalex Biosciences Expands CNS Platform to Advance Treatment for Restless Legs Syndrome with Augmentation

    License agreement secures potential research of ecopipam for [...]

  • December 16, 2021

    Outstanding 2021 for Paragon Biosciences and Our Portfolio Companies

    Chicago, Dec. 16, 2021 – Paragon Biosciences has [...]

  • December 7, 2021

    PARAGON BIOSCIENCES EARNS 2021 GREAT PLACE TO WORK™ CERTIFICATION

    Chicago, Dec. 7, 2021 – Paragon Biosciences [...]

  • November 10, 2021

    Paragon’s Portfolio Company Emalex Biosciences Announces Positive Topline Results from Phase 2b Clinical Study Evaluating Ecopipam for Pediatric Tourette Syndrome

    Statistically significant, clinically meaningful results obtained on the [...]

  • September 14, 2021

    Emalex Biosciences Recruiting People Who Stutter for Phase 2 Clinical Trial for Childhood-Onset Fluency Disorder

    Current enrollment for stuttering study is at 75%; [...]